We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
NAB-PACLITAXEL ACCORD (Accord Healthcare Pty Ltd)
Product name
NAB-PACLITAXEL ACCORD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
151 (255 working days)
Active ingredients
paclitaxel
Registration type
New generic medicine
Indication
NAB-PACLITAXEL ACCORD
- Metastatic Breast Cancer
NAB-PACLITAXEL ACCORD is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.
- Non-small Cell Lung Cancer
NAB-PACLITAXEL ACCORD, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation.
- Metastatic Adenocarcinoma of the Pancreas
NAB-PACLITAXEL ACCORD, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
NAB-PACLITAXEL INTAS
- Metastatic Breast Cancer
NAB-PACLITAXEL INTAS is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.